Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.

Cancer discovery - 1 Sept 2015

Tricker Erin M, Xu Chunxiao, Uddin Sharmeen, Capelletti Marzia, Ercan Dalia, Ogino Atsuko, Pratilas Christine A, Rosen Neal, Gray Nathanael S, Wong Kwok-Kin, Jänne Pasi A

Abstract excerpt

UNLABELLED: Irreversible pyrimidine-based EGFR inhibitors, including WZ4002, selectively inhibit both EGFR-activating and EGFR inhibitor-resistant T790M mutations more potently than wild-type EGFR. Although this class of mutant-selective EGFR inhibitors is effective clinically in lung cancer patients harboring EGFR(T790M), prior preclinical studies demonstrate that acquired resistance can occur through genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Kinase Inhibitors

Share to Ribosomal Protein S6 Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26036643
DOI: 10.1158/2159-8290.CD-15-0063
PMCID: PMC4824006

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.PMID 26036643Read ↗

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Semantic proximity Read ↗

EGFR-TKIs resistance via EGFR-independent signaling pathways.Semantic proximity Read ↗

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung CancerSemantic proximity Read ↗

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.Semantic proximity Read ↗

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.Semantic proximity Read ↗

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppressionSemantic proximity Read ↗

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesSemantic proximity Read ↗

RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Semantic proximity Read ↗

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.Semantic proximity Read ↗

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.Semantic proximity Read ↗

Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.Semantic proximity Read ↗

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.